ALZPATH - LICENSING FOR USE OF ITS PROPRIETARY PTAU217 ANTIBODY IN DEVELOPMENT OF A PTAU217 ASSAY IN EXPANDING MENU OF SIEMENS HEALTHINEERS IN VITRO DIAGNOSTIC (IVD) TESTS FOR ALZHEIMER'S DISEASE

Reuters · 4d ago

Please log in to view news